• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Clin Med Intensive Care Risk Estimation in COVID-19 Pneumonia Based on Clinical and Imaging Parameters: Experiences From the Munich Cohort

tetano

Editor, Senior Moderator
J Clin Med


. 2020 May 18;9(5):E1514.
doi: 10.3390/jcm9051514.
Intensive Care Risk Estimation in COVID-19 Pneumonia Based on Clinical and Imaging Parameters: Experiences From the Munich Cohort


Egon Burian[SUP] 1 2 [/SUP], Friederike Jungmann[SUP] 1 [/SUP], Georgios A Kaissis[SUP] 1 [/SUP], Fabian K Loh?fer[SUP] 1 [/SUP], Christoph D Spinner[SUP] 3 [/SUP], Tobias Lahmer[SUP] 3 [/SUP], Matthias Treiber[SUP] 3 [/SUP], Michael Dommasch[SUP] 4 [/SUP], Gerhard Schneider[SUP] 5 [/SUP], Fabian Geisler[SUP] 3 [/SUP], Wolfgang Huber[SUP] 3 [/SUP], Ulrike Protzer[SUP] 6 [/SUP], Roland M Schmid[SUP] 3 [/SUP], Markus Schwaiger[SUP] 7 [/SUP], Marcus R Makowski[SUP] 1 [/SUP], Rickmer F Braren[SUP] 1 [/SUP]



Affiliations

Abstract

The evolving dynamics of coronavirus disease 2019 (COVID-19) and the increasing infection numbers require diagnostic tools to identify patients at high risk for a severe disease course. Here we evaluate clinical and imaging parameters for estimating the need of intensive care unit (ICU) treatment. We collected clinical, laboratory and imaging data from 65 patients with confirmed COVID-19 infection based on polymerase chain reaction (PCR) testing. Two radiologists evaluated the severity of findings in computed tomography (CT) images on a scale from 1 (no characteristic signs of COVID-19) to 5 (confluent ground glass opacities in over 50% of the lung parenchyma). The volume of affected lung was quantified using commercially available software. Machine learning modelling was performed to estimate the risk for ICU treatment. Patients with a severe course of COVID-19 had significantly increased interleukin (IL)-6, C-reactive protein (CRP), and leukocyte counts and significantly decreased lymphocyte counts. The radiological severity grading was significantly increased in ICU patients. Multivariate random forest modelling showed a mean ? standard deviation sensitivity, specificity and accuracy of 0.72 ? 0.1, 0.86 ? 0.16 and 0.80 ? 0.1 and a receiver operating characteristic-area under curve (ROC-AUC) of 0.79 ? 0.1. The need for ICU treatment is independently associated with affected lung volume, radiological severity score, CRP, and IL-6.

Keywords: COVID-19; clinical parameters; computed tomography; intensive care unit; radiological parameters; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
 
Back
Top Bottom